We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic ...

LONDON - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company engaged in developing treatments for ocular conditions, has reported insider share purchases on the NASDAQ. The company's CEO, ...

OKYO Pharma's CEO and Executive Chairman purchased shares, increasing their stake as the company develops treatments for eye conditions. OKYO Pharma Limited, a clinical-stage biopharmaceutical ...

LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of ...

If an award of orphan drug designation to NCP, should happen, it could lead to a multi-billion dollar market opportunity for OKYO. In the Opportunity Research report, analyst Rob Goldman reviews ...